GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
US6720323B2
(en)
|
2000-07-07 |
2004-04-13 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as angiogenesis inhibitors
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
EP1474420B1
(en)
|
2002-02-01 |
2012-03-14 |
AstraZeneca AB |
Quinazoline compounds
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
DE60318219T2
(de)
|
2002-08-24 |
2009-01-15 |
Astrazeneca Ab |
PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
MY136174A
(en)
|
2002-12-24 |
2008-08-29 |
Astrazeneca Ab |
Phosphonooxy quinazoline derivatives and their pharmaceutical use
|
US8198302B2
(en)
|
2003-02-28 |
2012-06-12 |
Oxigene, Inc. |
Compositions and methods with enhanced therapeutic activity
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
DK1689233T3
(da)
|
2003-11-19 |
2012-10-15 |
Array Biopharma Inc |
Bicykliske inhibitorer af MEK
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
CN100584840C
(zh)
|
2004-01-05 |
2010-01-27 |
阿斯利康(瑞典)有限公司 |
取代杂环化合物及其应用
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
JP4795352B2
(ja)
|
2004-08-28 |
2011-10-19 |
アストラゼネカ・アクチエボラーグ |
ケモカイン受容体モジュレーターとしてのピリミジンスルホンアミド誘導体
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
PT2383268E
(pt)
|
2005-02-04 |
2015-12-21 |
Astrazeneca Ab |
Derivados de pirazolilaminopiridina úteis como inibidores de quinase
|
ES2333182T3
(es)
|
2005-05-18 |
2010-02-17 |
Array Biopharma, Inc. |
Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas.
|
ES2397418T3
(es)
|
2005-07-21 |
2013-03-06 |
Astrazeneca Ab |
Derivados de piperidina
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
JPWO2007034882A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
EP1939200A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
EP1939198A4
(en)
|
2005-09-22 |
2012-02-15 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
JPWO2007034917A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規なアデニン化合物
|
US20090118263A1
(en)
|
2005-09-22 |
2009-05-07 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel Adenine Compound
|
EP1937632A1
(en)
|
2005-10-06 |
2008-07-02 |
Astra Zeneca AB |
Novel compounds
|
EP1945631B8
(en)
|
2005-10-28 |
2013-01-02 |
AstraZeneca AB |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
ES2364901T3
(es)
|
2005-11-15 |
2011-09-16 |
Array Biopharma, Inc. |
Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
PT1979001E
(pt)
|
2005-12-13 |
2012-07-13 |
Medimmune Ltd |
Proteínas de ligação específicas para factores de crescimento insulínicos e suas aplicações
|
JP2009519308A
(ja)
|
2005-12-15 |
2009-05-14 |
アストラゼネカ・アクチエボラーグ |
呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
JP2009538289A
(ja)
|
2006-05-26 |
2009-11-05 |
アストラゼネカ・アクチエボラーグ |
ビアリールまたはヘテロアリール置換インドール
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
SI2057156T1
(sl)
|
2006-08-23 |
2017-06-30 |
Kudos Pharmaceuticals Limited |
Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
JP4604129B2
(ja)
|
2006-12-19 |
2010-12-22 |
アストラゼネカ・アクチエボラーグ |
ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
MX2010003698A
(es)
|
2007-10-04 |
2010-04-21 |
Astrazeneca Ab |
Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide.
|
AU2008309383B2
(en)
|
2007-10-11 |
2012-04-19 |
Astrazeneca Ab |
Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
EP2604628A3
(en)
|
2007-12-21 |
2013-08-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4R) - 173
|
PL2242759T3
(pl)
|
2008-02-06 |
2013-06-28 |
Astrazeneca Ab |
Związki
|
AU2009219376B2
(en)
|
2008-02-28 |
2014-09-25 |
Merck Patent Gmbh |
Protein kinase inhibitors and use thereof
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
EP2297106B1
(en)
|
2008-05-27 |
2014-07-16 |
AstraZeneca AB |
Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
EP2373326B1
(en)
|
2008-12-11 |
2016-03-09 |
Axcentua Pharmaceutucals AB |
Crystalline forms of genistein
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
EP2367821B1
(en)
|
2008-12-17 |
2015-09-16 |
Merck Patent GmbH |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
EP2367822B1
(en)
|
2008-12-18 |
2016-10-05 |
Merck Patent GmbH |
Tricyclic azaindoles
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
US20110053923A1
(en)
|
2008-12-22 |
2011-03-03 |
Astrazeneca |
Chemical compounds 610
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
WO2010092371A1
(en)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
WO2011039528A1
(en)
|
2009-10-02 |
2011-04-07 |
Astrazeneca Ab |
2-pyridone compounds used as inhibitors of neutrophil elastase
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
RU2542582C2
(ru)
|
2009-11-18 |
2015-02-20 |
Астразенека Аб |
Производные бензимидазола, полезные при лечении состояний, ассоциированных с активностью р2х3 или р2х2/3
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
AU2010333338A1
(en)
|
2009-12-14 |
2012-08-02 |
Merck Patent Gmbh |
Sphingosine kinase inhibitors
|
KR20120096076A
(ko)
|
2009-12-17 |
2012-08-29 |
메르크 파텐트 게엠베하 |
스핑고신 키나아제 저해제
|
AU2011206864B2
(en)
|
2010-01-15 |
2013-12-19 |
Suzhou Neupharma Co., Ltd. |
Certain chemical entities, compositions, and methods
|
CA2786520A1
(en)
|
2010-01-19 |
2011-07-28 |
Astrazeneca Ab |
Pyrazine derivatives
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
TW201219383A
(en)
|
2010-08-02 |
2012-05-16 |
Astrazeneca Ab |
Chemical compounds
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
JP2013542916A
(ja)
|
2010-11-19 |
2013-11-28 |
大日本住友製薬株式会社 |
環状アミド化合物および疾患の処置におけるその使用
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
CN103370317B
(zh)
|
2010-12-16 |
2015-10-07 |
阿斯利康(瑞典)有限公司 |
可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
|
WO2012080730A1
(en)
|
2010-12-17 |
2012-06-21 |
Astrazeneca Ab |
Purine derivatives
|
MX2013007067A
(es)
|
2010-12-20 |
2013-11-01 |
Medimmune Ltd |
Anticuerpos anti-il-18 y sus usos.
|
US9493503B2
(en)
|
2011-02-02 |
2016-11-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
JP5937111B2
(ja)
|
2011-02-17 |
2016-06-22 |
カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited |
Fak阻害剤
|
CA2827172C
(en)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
RS61608B1
(sr)
|
2011-07-12 |
2021-04-29 |
Astrazeneca Ab |
N- (6 - ((2r, 3s) -3,4-dihidroksibutan-2-iloksi) -2- (4-fluorobenziltio) pirimidin-4-il) -3- metilazetidin-1-sulfonamid kao modulator receptora hemokina
|
EP3686193B1
(en)
|
2011-07-27 |
2022-03-02 |
Astrazeneca AB |
2-(2,4,5-substituted-anilino)pyrimidine compounds
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
CN104053442B
(zh)
|
2011-08-26 |
2017-06-23 |
润新生物公司 |
某些化学实体、组合物及方法
|
WO2013033250A1
(en)
|
2011-09-01 |
2013-03-07 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
JP6093768B2
(ja)
|
2011-09-14 |
2017-03-08 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
EP2760458B1
(en)
|
2011-09-29 |
2017-06-14 |
The University of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
WO2013049701A1
(en)
|
2011-09-30 |
2013-04-04 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
WO2013112950A2
(en)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
SG11201404234YA
(en)
|
2012-01-28 |
2014-08-28 |
Merck Patent Gmbh |
Triazolo[4,5-d]pyrimidine derivatives
|
SG11201404654SA
(en)
|
2012-02-09 |
2014-09-26 |
Merck Patent Gmbh |
Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
|
ES2606637T3
(es)
|
2012-02-09 |
2017-03-24 |
Merck Patent Gmbh |
Derivados de furo [3,2- b]piridina como inhibidores de TBK1 e IKK
|
WO2013126132A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
ES2674451T3
(es)
|
2012-02-21 |
2018-06-29 |
Merck Patent Gmbh |
2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
|
ES2606638T3
(es)
|
2012-02-21 |
2017-03-24 |
Merck Patent Gmbh |
Derivados de furopiridina
|
WO2013131609A1
(en)
|
2012-03-07 |
2013-09-12 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
EP2831077B1
(en)
|
2012-03-28 |
2016-04-27 |
Merck Patent GmbH |
Bicyclic pyrazinone derivatives
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
AU2013244999A1
(en)
|
2012-04-05 |
2014-09-25 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human TWEAK and human IL17 and uses thereof
|
US9676813B2
(en)
|
2012-04-29 |
2017-06-13 |
Neupharma, Inc. |
Certain steroids and methods for using the same in the treatment of cancer
|
CA2872334C
(en)
|
2012-05-04 |
2020-06-30 |
Dieter Dorsch |
Pyrrolotriazinone derivatives
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
JP6430936B2
(ja)
|
2012-07-24 |
2018-11-28 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
関節症の処置のためのヒドロキシスタチン誘導体
|
EP2882746B1
(en)
|
2012-08-07 |
2016-12-07 |
Merck Patent GmbH |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
PL2882714T3
(pl)
|
2012-08-08 |
2020-02-28 |
Merck Patent Gmbh |
Pochodne (aza-)izochinolinonowe
|
CA2882158A1
(en)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014047648A1
(en)
|
2012-09-24 |
2014-03-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
SG11201502120XA
(en)
|
2012-09-26 |
2015-04-29 |
Merck Patent Gmbh |
Quinazolinone derivatives as parp inhibitors
|
JP6348115B2
(ja)
|
2012-10-26 |
2018-06-27 |
ザ ユニバーシティー オブ クイーンズランド |
がん療法のためのエンドサイトーシス阻害剤および抗体の使用
|
EP2914750B1
(en)
|
2012-11-05 |
2018-04-18 |
GMDx Co Pty Ltd |
Methods for determining the cause of somatic mutagenesis
|
EP2916838B1
(en)
|
2012-11-12 |
2019-03-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
MX2015006037A
(es)
|
2012-11-16 |
2015-08-07 |
Merck Patent Gmbh |
Derivados de 3-aminociclopentancarboxamida.
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
CN105246888B
(zh)
|
2013-01-31 |
2017-09-05 |
尼奥迈德研究所 |
咪唑并吡啶化合物及其用途
|
CN105189469B
(zh)
|
2013-02-25 |
2018-09-25 |
默克专利股份公司 |
2-氨基-3,4-二氢喹唑啉衍生物及其作为组织蛋白酶d抑制剂的用途
|
WO2014135245A1
(en)
|
2013-03-05 |
2014-09-12 |
Merck Patent Gmbh |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
CA2905509A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Hsp90-targeted cardiac imaging and therapy
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
CN105142648A
(zh)
|
2013-03-15 |
2015-12-09 |
玛格塞蒂克斯公司 |
用于癌症的镁组合物及其用途
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
EP3004073A1
(en)
|
2013-06-07 |
2016-04-13 |
Université catholique de Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
WO2014205511A1
(en)
|
2013-06-25 |
2014-12-31 |
University Of Canberra |
Methods and compositions for modulating cancer stem cells
|
SG11201601138PA
(en)
|
2013-08-23 |
2016-03-30 |
Neupharma Inc |
Certain chemical entities, compositions, and methods
|
CN105764513A
(zh)
|
2013-09-18 |
2016-07-13 |
堪培拉大学 |
干细胞调控ii
|
WO2015048852A1
(en)
|
2013-10-01 |
2015-04-09 |
The University Of Queensland |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
EP3185858A4
(en)
|
2014-08-25 |
2017-12-27 |
University of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
AU2015349613B2
(en)
|
2014-11-17 |
2022-01-13 |
The Council Of The Queensland Institute Of Medical Research |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
AU2016220219B2
(en)
|
2015-02-17 |
2020-05-14 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
CA2994023A1
(en)
|
2015-08-04 |
2017-02-02 |
University Of South Australia |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
US11225690B2
(en)
|
2015-08-26 |
2022-01-18 |
Gmdx Co Pty Ltd |
Methods of detecting cancer recurrence
|
SG11201805341RA
(en)
|
2015-12-23 |
2018-07-30 |
Univ Queensland Technology |
Nucleic acid oligomers and uses therefor
|
WO2017132728A1
(en)
|
2016-02-01 |
2017-08-10 |
University Of Canberra |
Proteinaceous compounds and uses therefor
|
CN109073650A
(zh)
|
2016-02-15 |
2018-12-21 |
阿斯利康(瑞典)有限公司 |
包括对西地尼布进行固定的间歇给药的方法
|
WO2017178845A1
(en)
|
2016-04-15 |
2017-10-19 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
JP6985388B2
(ja)
|
2016-07-29 |
2021-12-22 |
ラプト・セラピューティクス・インコーポレイテッド |
ケモカイン受容体調節剤及びそれの使用
|
JP7101165B2
(ja)
|
2016-08-15 |
2022-07-14 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
EP3515903B1
(en)
|
2016-09-22 |
2020-10-21 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
US10287253B2
(en)
|
2016-12-05 |
2019-05-14 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
AU2018214431B2
(en)
|
2017-02-01 |
2021-07-29 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
EP3630749B9
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
EP4374858A2
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
DK3630188T3
(da)
|
2017-05-31 |
2021-11-15 |
Amplio Pharma Ab |
Farmaceutisk sammensætning omfattende en kombination af methotrexat og novobiocin og anvendelse af sammensætningen til behandling
|
EP3648797A1
(en)
|
2017-07-05 |
2020-05-13 |
EPOS-Iasis Research and Development, Ltd |
Multifunctional conjugates
|
SG11202000823WA
(en)
|
2017-08-01 |
2020-02-27 |
Merck Patent Gmbh |
Thiazolopyridine derivatives as adenosine receptor antagonists
|
CN111278840B
(zh)
|
2017-08-18 |
2023-11-17 |
癌症研究科技有限公司 |
吡咯并[2,3-b]吡啶化合物及其治疗癌症的用途
|
TW201920123A
(zh)
|
2017-08-21 |
2019-06-01 |
德商馬克專利公司 |
作為腺苷受體拮抗劑之喹㗁啉衍生物
|
AU2018320673B2
(en)
|
2017-08-21 |
2023-03-30 |
Merck Patent Gmbh |
Benzimidazole derivatives as adenosine receptor antagonists
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
AU2018360766A1
(en)
|
2017-11-06 |
2020-05-21 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
EP3488868B1
(en)
|
2017-11-23 |
2023-09-13 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
AU2019207517A1
(en)
|
2018-01-15 |
2020-08-27 |
Aucentra Therapeutics Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
JP7355758B2
(ja)
|
2018-01-26 |
2023-10-03 |
ラプト・セラピューティクス・インコーポレイテッド |
ケモカイン受容体調節剤及びその使用
|
AU2019218893A1
(en)
|
2018-02-08 |
2020-09-03 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
MX2020010805A
(es)
|
2018-04-13 |
2021-01-29 |
Cancer Research Tech Ltd |
Inhibidores de bcl6.
|
EP3784233B1
(en)
|
2018-04-27 |
2024-06-05 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
CN112513031A
(zh)
|
2018-06-04 |
2021-03-16 |
阿普罗斯治疗公司 |
可用于治疗与tlr7调节相关的疾病的含酸性基团的嘧啶化合物
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
KR20210061329A
(ko)
|
2018-09-18 |
2021-05-27 |
수저우 잔롱 파마 리미티드 |
항종양제로서의 퀴나졸린 유도체
|
WO2020068600A1
(en)
|
2018-09-24 |
2020-04-02 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
|
JP2022505872A
(ja)
|
2018-10-25 |
2022-01-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
|
ES2960883T3
(es)
|
2018-10-25 |
2024-03-07 |
Merck Patent Gmbh |
Derivados de 5-azaindazol como antagonistas de los receptores de adenosina
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
CN114729354A
(zh)
|
2018-12-25 |
2022-07-08 |
中国医学科学院基础医学研究所 |
炎性相关疾病防治的小rna药物及其组合
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
JP2022524759A
(ja)
|
2019-03-07 |
2022-05-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
JP2022528562A
(ja)
|
2019-04-05 |
2022-06-14 |
ストーム・セラピューティクス・リミテッド |
Mettl3阻害化合物
|
WO2020210384A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
CA3152674A1
(en)
|
2019-08-31 |
2021-03-04 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole derivatives for fgfr inhibitor and preparation method thereof
|
MX2022003276A
(es)
|
2019-09-20 |
2022-04-11 |
Ideaya Biosciences Inc |
Derivados de indol e indazol sulfonamido sustituidos en la posicion 4 como inhibidores de parg.
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
CA3162166A1
(en)
|
2019-12-02 |
2021-06-10 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as mettl3 inhibitors
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202008201D0
(en)
|
2020-06-01 |
2020-07-15 |
Neophore Ltd |
Inhibitor compounds
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
EP4333900A2
(en)
|
2021-05-03 |
2024-03-13 |
Merck Patent GmbH |
Her2 targeting fc antigen binding fragment-drug conjugates
|
TW202306568A
(zh)
|
2021-05-17 |
2023-02-16 |
南韓商怡諾安有限公司 |
苯甲醯胺衍生物、包含其之醫藥組成物、包含其之健康功能食品組成物、包含其之組合製劑、及其用途
|
CN117999101A
(zh)
|
2021-05-25 |
2024-05-07 |
默克专利股份公司 |
靶向EGFR的Fc抗原结合片段-药物缀合物
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
WO2023057389A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
WO2023131690A1
(en)
|
2022-01-10 |
2023-07-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2023218201A1
(en)
|
2022-05-11 |
2023-11-16 |
Cancer Research Technology Limited |
Ikk inhibitors
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|